A 5-year Longitudinal Observational Study of Patients Undergoing


ID# NCT03661866

Recruitment Status: Recruiting

Estimated Study Completion Date: December 31, 2026

HS Connect listed this: October 2020


Sponsor: Target PharmaSolutions, Inc.

Information provided by (Responsible Party): Target PharmaSolutions, Inc.


Brief Summary:


TARGET-DERM is a 5-year, longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.


Please link for complete trial details:






Multiple US locations. Please see link provided above for all location details and to confirm your location is recruiting.


Contact Information: 


Contact: Laura Dalfonso Phone: 9842340268

Email: ldalfonso@targetpharmasolutions.com


Laura Malahias Phone: 9842340268 ext 209

Email: lmalahias@targetpharmasolutions.com


© 2021 by HS Connect, LLC  |  HSConnect.org@gmail.com  |  PO Box 73244 Puyallup, WA 98373  |  253.256.1579